Fractyl Laboratories Inc (Ticker: GUTS US) is a healthcare-provision company focused on developing innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company aims to transform metabolic disease treatment by targeting the root causes of these conditions at the organ level, moving beyond symptomatic management towards more durable, disease-modifying approaches.

Fractyl Laboratories Inc will list on the NASDAQ Global Market in the United States. The company expects to raise USD 117.33 million through its initial public offering. It is offering 7.33 million shares with an expected price range of USD 14.00 to 16.00 per share. Additionally, there is a greenshoe option of 15%, corresponding to 1.10 million shares. The expected trading date is set for February 2, 2024.

Fractyl Laboratories’ pipeline consists of two treatments: Revita®, an ablative procedure to remove unhealthy mucosal membranes in the gut, currently for investigational use only in the U.S., and Rejuva®, which is a GLP-1 diabetes treatment gene therapy in early development.